How Weight Loss Pills Have Changed — and What That Means for Safety

“[Obesity] is a lifelong disease that requires lifelong intervention, and even when people make lifestyle changes, they still have to fight against weight gain,” says Timothy Garvey, MD, a professor in the department of nutrition sciences and the director of the Diabetes Research Center at the University of Alabama in Birmingham. “Medications can stop the processes that cause this weight gain.”
Early Weight Loss Drugs
“None of these medications were tested in long-term trials prior to repurposing them for the treatment of obesity. This raises the risk that they will have side effects not recognized in short-term therapy,” says Frank Greenway, MD, the chief medical officer and a professor at the Pennington Biomedical Research Center at Louisiana State University in Baton Rouge.
Tougher Drug Testing Requirements
All the medications approved in the last decade have a good track record of safety so far, says Adam Gilden, MD, an associate professor and obesity researcher at the University of Colorado School of Medicine in Aurora. These newer drugs either combine medicines that have good safety records when used individually or those that have been used for a long time to manage type 2 diabetes before gaining traction as obesity treatments.
“So, we can feel good that these medicines are safe,” Dr. Gilden says. “Also, every one of these medicines will be subjected to large post-marketing trials, which will further assess safety and longer-term efficacy.”
“I think it is a very exciting time for obesity medicine because we now have several effective treatments to choose from,” says Melanie Jay, MD, an obesity researcher and a professor at the New York University Grossman School of Medicine in New York City.
Weight Loss Drug Options
For many patients today, a decision about which weight loss medication to try may come down to several factors, including what other medications they take, which drugs are covered by insurance or are most affordable, and whether people prefer pills or injected medicines, Dr. Jay says.
“I advise people to speak to their physician to choose an initial medication and see how they respond,” Jay says. “It’s not uncommon to switch medications or have to add a second or third medication.”
Here’s what you need to know about the prescription weight loss drugs that are currently approved.
Tirzepatide (Zepbound)
Common side effects: Nausea, diarrhea, vomiting, and constipation.
Interactions and risks: Rare but potentially dangerous reactions include severe gastrointestinal disease and acute injury to the pancreas, kidneys, or gallbladder.
Semaglutide (Wegovy)
How it works: It’s another GLP-1 receptor agonist that mimics a hormone in the brain that regulates appetite.
Common side effects: Nausea, diarrhea, vomiting, constipation, stomach pain, headache, and fatigue.
Interactions and risks: It can’t be used in combination with liraglutide or other GLP-1 receptor agonists that are prescribed for type 2 diabetes. Like other drugs in this family of medicines, including tirzepatide and liraglutide, it carries an increased risk of pancreatitis and has been linked to thyroid tumors in animals.
Naltrexone-Bupropion (Contrave)
How it works: It’s a combination of two drugs that are used to treat addiction and depression, and it suppresses appetite and makes people feel full sooner.
Common side effects: Constipation, dizziness, diarrhea, dry mouth, headache, increased blood pressure, elevated heart rate, insomnia, liver damage, nausea, and vomiting.
Interactions and risks: It shouldn’t be used by people with uncontrolled blood pressure, seizures, a history of anorexia or bulimia, people taking psychiatric drugs containing bupropion (Wellbutrin, Zyban), or individuals dependent on opioids or in withdrawal from drugs or alcohol. It can increase suicidal thoughts or actions.
Liraglutide (Saxenda)
How it works: It’s in a family of medicines known as glucagon-like peptide-1 (GLP-1) receptor agonists, which work by mimicking a hormone in the brain that regulates appetite and food consumption.
Common side effects: Nausea, diarrhea, constipation, abdominal pain, headache, and increased heart rate. Rare side effects include an increased risk of pancreatitis, and it’s been linked to thyroid tumors in animals.
Interactions and risks: In a smaller dose, liraglutide is used as a diabetes medication called Victoza, which should not be used in conjunction with Saxenda.
Phentermine-Topiramate (Qsymia)
How it works: This combination pill suppresses appetite and makes people feel full sooner.
Common side effects: Constipation, dizziness, dry mouth, tingling in hands and feet, brain fog or cognitive impairment, and difficulty sleeping.
Interactions and risks: It shouldn’t be used by people with glaucoma or hyperthyroidism, by women who are pregnant or breastfeeding, or by some individuals with a history of heart attack, stroke, heart rhythm disorders, kidney disease, or mood problems.
Orlistat (Xenical, Alli)
How it works: It works in the gut to limit the amount of fat absorbed from foods you eat.
Common side effects: Diarrhea, gas, stomach pain, and oily stool leakage.
What to Consider Before Taking Weight Loss Pills
The Takeaway
- For many people with obesity who struggle to shed excess pounds, prescription weight loss drugs can help when lifestyle changes like calorie restriction and exercise aren’t enough.
- So far, drugs approved within the past decade have proved safer than earlier weight loss drugs.
- Before starting weight loss medication, discuss your options with a healthcare provider to learn about potential risks and side effects.
Resources We Trust
- Mayo Clinic: Prescription Weight Loss Drugs
- Cleveland Clinic: Weight Loss Medications
- American Diabetes Association: Oral & Injectable Medications for Type 2 Diabetes
- National Institute of Diabetes and Digestive and Kidney Diseases: Prescription Medications to Treat Overweight & Obesity
- American Medical Association: Questions Patients May Have About Weight Loss Drugs
- Witters D et al. Obesity Rate Declining in U.S. Gallup. October 28, 2025.
- Masood B et al. Causes of Obesity: A Review. Clinical Medicine. July 2023.
- Prescription Medications to Treat Overweight and Obesity. National Institute of Diabetes and Digestive and Kidney Diseases. June 2024.
- Saxon DR et al. Anti-Obesity Medication Use in 2.2 Million Adults Across 8 Large Healthcare Organizations: 2009-2015. Obesity. October 11, 2019.
- Bray GA et al. An Historical Review of Steps and Missteps in the Discovery of Anti-Obesity Drugs. Endotext. July 10, 2022.
- FDA Drug Safety Communication: FDA Recommends Against the Continued Use of Meridia (sibutramine). U.S. Food and Drug Administration. February 6, 2018.
- FDA Requests the Withdrawal of the Weight-Loss Drug Belviq, Belviq Xr (Lorcaserin) From the Market. U.S. Food and Drug Administration. February 13, 2020.
- Colman E. Food and Drug Administration's Obesity Drug Guidance Document: A Short History. Circulation. May 1, 2012.
- FDA Approves New Medication for Chronic Weight Management. U.S. Food and Drug Administration. November 8, 2023.
- Jastreboff A et al. Tirzepatide Once Weekly for the Treatment of Obesity. The New England Journal of Medicine. June 4, 2022.
- FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight. U.S. Food and Drug Administration. March 8, 2024.
- Novo Nordisk A/S: Wegovy Pill Approved in the US as First Oral Glp-1 for Weight Management. Novo Nordisk. December 22, 2025.
- Approval Package for: 200063Orig1s000. Center for Drug Evaluation and Research. September 10, 2014.
- FDA Approves Weight Management Drug for Patients Aged 12 and Older. U.S. Food and Drug Administration. June 15, 2021.
- FDA Approves Treatment for Chronic Weight Management in Pediatric Patients Aged 12 Years and Older. U.S. Food and Drug Administration. June 27, 2022.
- Orlistat (Marketed as Alli and Xenical) Information. U.S. Food and Drug Administration. July 8, 2015.
- Munoz-Mantilla D. Top Weight Loss Medications. Obesity Medicine Association. July 29, 2025.
- Sauerwein K. Study Identifies Benefits, Risks Linked to Popular Weight-Loss Drugs. WashU Medicine. January 20, 2025.
- Chiappini S et al. Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration’s FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset. Pharmaceuticals. July 11, 2023.
- WHO Issues Global Guideline on the Use of GLP-1 Medicines in Treating Obesity. World Health Organization. December 1, 2025.

Sean Hashmi, MD
Medical Reviewer
Sean Hashmi, MD, is an experienced nephrologist and obesity medicine specialist based in Southern California. As the regional director for clinical nutrition and weight management at a prominent healthcare organization in Southern California, Dr. Hashmi oversees the development and implementation of cutting-edge nutritional programs and weight management strategies. With his innovative approach and unwavering commitment to providing evidence-based solutions, he is a highly sought-after speaker and a leader in his field.
Hashmi founded the nonprofit organization SelfPrinciple.org to provide accessible and accurate health, nutrition, and wellness information to the public. Through this platform, he shares the latest research findings, empowering individuals to make informed decisions about their well-being. Self Principle also supports children's education by providing scholarships, books, and supplies, so that students have the resources necessary to succeed academically and build a brighter future.
